Checkpoint Kinase 2 Gene Mutation clinical trials at University of California Health
1 research study open to eligible people
Showing trials for
Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors
open to eligible people ages 18 years and up
This is a single center, phase I/Ib clinical trial evaluating the combination of the poly adenosine diphosphate-ribose polymerase (PARP) inhibitor olaparib with the DNA methyltransferase (DNMT) inhibitor ASTX727, which is an oral formulation of…
at UCSF
Our lead scientists for Checkpoint Kinase 2 Gene Mutation research studies include Pamela Munster, MD.
Last updated: